Stephen Gately Discusses Precision Medicine in Applied Clinical Trials

June 22, 2018

Cancer is now classified not only by the organ of origin, but by genomic and proteomic profiling.

These “omic” contexts allow drug developers to target tailored treatments even to the rarest of cancers. TD2 CEO, Stephen Gately, shares how cancers can be a rare cancers when you consider their various molecular defects, and how drug developers can focus development of new medicines against these unique “omic” contexts in a recent article published in Applied Clinical Trials.

“Precision medicine provides physicians with the opportunity to avoid less effective treatments and focus on rationally selected medicines that improve clinical outcomes for patients,” said Gately.

Read more about Gately’s outlook on the future of precision medicine in cancer treatment research in the full article.

Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know

The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...

Read more +

Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus

In June 2025, the FDA announced a major shift in regulatory guidance: the elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements ...

Read more +

The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know

Traditional mouse models remain a cornerstone of preclinical oncology research. Syngeneic and xenografts mouse models continue to play a critical ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.